LBP AM SA lowered its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,787 shares of the company's stock after selling 8,014 shares during the quarter. LBP AM SA's holdings in Zoetis were worth $17,253,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. lifted its position in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC bought a new position in Zoetis during the 4th quarter valued at about $30,000. Cornerstone Planning Group LLC raised its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the period. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis during the 4th quarter worth approximately $44,000. Finally, Sound Income Strategies LLC boosted its holdings in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares during the period. Institutional investors own 92.80% of the company's stock.
Insider Buying and Selling at Zoetis
In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.18% of the stock is currently owned by company insiders.
Zoetis Stock Performance
Shares of NYSE ZTS traded down $3.89 during mid-day trading on Friday, hitting $154.91. The stock had a trading volume of 2,267,443 shares, compared to its average volume of 2,588,962. The firm has a market cap of $68.97 billion, a PE ratio of 27.81, a PEG ratio of 2.62 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The company has a 50 day moving average of $161.37 and a two-hundred day moving average of $161.93. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.
Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm's revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.38 earnings per share. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.29%. Zoetis's payout ratio is 35.91%.
Analysts Set New Price Targets
ZTS has been the subject of a number of recent analyst reports. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $212.13.
Check Out Our Latest Stock Analysis on ZTS
Zoetis Company Profile
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
